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A corrigendum on
Glycobiology of neuroblastoma: impact
on tumor behavior, prognosis, and thera-
peutic strategies
by Berois N and Osinaga E. Front Oncol
(2014) 4:114. doi: 10.3389/fonc.2014.00114
The glycosyltransferases B4GALNT3 and
B4GALT3 were mistakenly analyzed as
B4GALNT3 in this review. The Table 1 was
changed and the text in the last paragraph
of “Glycosyltransferases as tumor markers
in NB patients” was modified as follows.
Table 1 | Glycosyltransferases as neuroblastoma (NB) tumor markers.
Enzyme Method/sample Clinical significance Reference
β1,4-N -acetylgalactosaminyltransferase
(GD2 synthase)
ICC/bone marrow Molecular marker of metastatic NB J Clin Oncol ; 4:363–369 (1986)
RT-PCR ECL/bone marrow Molecular marker of metastatic NB Cancer; 92:924–931 (2001)
RT-PCR ECL/bone marrow Molecular marker of metastatic NB Am J Pathol; 159:493–500 (2001)
qRT-PCR/bone marrow Marker for minimal residual disease J Clin Oncol; 21:1087–1093 (2003)
qRT-PCR/bone marrow-PB Prognostic marker (poor outcome) Int J Cancer; 123:2849–2855 (2008)
Sialyltransferase STX (ST8SiaII) qRT-PCR/bone marrow Molecular marker of metastatic NB Int. Cancer; 119:152–156 (2006)
N -acetylglucosaminyltransferase V (GnT-V) qRT-PCR/primary tumor Prognostic marker (better outcome) FEBS Lett; 580:627–632 (2006)
UDP-polypeptide GalNAc-transferase
13 (GalNAc-T13 – GALNT13)
RT-PCR/bone marrow Molecular marker of metastatic NB Clin Chem; 52:1701–1712 (2006)
UDP-polypeptide GalNAc-transferase
9 (GalNAc-T9 – GALNT9)
RT-PCR/primary tumor Prognostic marker (better outcome) Clin Chem; 59(1):225–233 (2013)
β1,3-N -acetylglucosaminyltransferase-3
(B3GNT3)
IHC/primary tumor Prognostic marker (better outcome) Cancer Sci; 104:1600–1608 (2013)
β1,4-N -acetylgalactosaminyltransferase
3 (B4GALNT3)
IHC/primary tumor Prognostic marker (better outcome) Am J Pathol; 179:1394–1404 (2011)
β-1,4-galactosyltransferase III (B4GALT3) IHC/primary tumor Prognostic marker (poor outcome) Clin Cancer Res; 19:1705–1716 (2013)
ICC, immunocytochemistry; RT-PCR, reverse transcriptase-polymerase chain reaction; ECL, electrochemiluminescence; PB, peripheral blood; IHC, immunohisto-
chemistry.
β1,4-N -acetylgalactosaminyltransferase
III (B4GALNT3) cloned by Sato et al.,
has been described as expressed in stom-
ach, colon, and testis (136). This enzyme
can transfer GalNAc residues to non-
reducing terminal GlcNAc-β leading to
the synthesis of GalNAcβ1–4GlcNAc (also
known as LacdiNAc or LDN), which is
a unique terminal structure in the outer
chain moieties of human N -glycans (137),
and also in O-linked oligosaccharide
structures (138). The largest amount of
B4GALNT3 transcripts were found in
gastric tissues, followed by colon, testis,
and adrenal glands (136). Gastric expres-
sion of B4GALNT3 was found regulated
by cellular differentiation (139). In the
human colon, Huang et al. reported
that B4GALNT3 is up-regulated in pri-
mary tumors comparing with the normal
mucosa (140). They performed in vitro
and in vivo experiments showing that
overexpression of this enzyme increases
malignant phenotype of colon cancer
cells, and these phenotypic changes are
associated with enhanced integrin and
mitogen-activated protein kinase (MAPK)
signaling, suggesting that B4GALNT3
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may play a crucial role in promoting
malignant behavior of colon cancer (140).
The same research team has recently pub-
lished that β-1,4-galactosyltransferase III
(B4GALT3) overexpression in colorectal
cancer cells suppressed cell migration,
invasion, and adhesion, while B4GALT3
knockdown enhanced malignant cell
phenotypes promoting cell migration
and invasion (141). Surprisingly, an
opposite situation was found for both
enzymes in NB. Firstly Hsu et al.
communicated that B4GALNT3 expres-
sion positively correlates with the dif-
ferentiation status of NB, predicting
a favorable prognosis for patients and
suppressing the malignant phenotype in
cell lines experiments via decreasing β1-
integrin signaling (142). By contrast, β-
1,4-galactosyltransferase III (B4GALT3)
expression in NB tumors correlated with
advanced clinical stage, unfavorable histol-
ogy, and lower survival rate (143). In con-
clusion, B4GALNT3 in NB seems a good
prognostic marker, while B4GALT3 was
suggested as poor outcome marker. Fur-
ther work is necessary to elucidate sub-
jacent molecular mechanisms for these
enzymes.
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